Farther Finance Advisors LLC Reduces Stock Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Farther Finance Advisors LLC cut its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 65.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,930 shares of the medical equipment provider’s stock after selling 3,699 shares during the quarter. Farther Finance Advisors LLC’s holdings in BioLife Solutions were worth $48,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Louisiana State Employees Retirement System increased its holdings in BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock worth $392,000 after purchasing an additional 700 shares during the last quarter. GAMMA Investing LLC increased its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in BioLife Solutions by 5.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 753 shares during the last quarter. Sei Investments Co. increased its holdings in BioLife Solutions by 1.4% during the 1st quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock worth $1,117,000 after purchasing an additional 839 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in BioLife Solutions by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock worth $281,000 after purchasing an additional 1,374 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at BioLife Solutions

In related news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,593,412.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,593,412.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the transaction, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,044 shares of company stock worth $645,105 in the last 90 days. 2.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on BLFS. Northland Securities lifted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. HC Wainwright assumed coverage on BioLife Solutions in a report on Monday, September 30th. They issued a “buy” rating and a $29.00 price target for the company. TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Craig Hallum boosted their price target on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.83.

BioLife Solutions Trading Down 9.0 %

NASDAQ:BLFS opened at $24.11 on Thursday. BioLife Solutions, Inc. has a 12-month low of $11.00 and a 12-month high of $28.88. The firm has a market capitalization of $1.11 billion, a P/E ratio of -22.75 and a beta of 1.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. The business has a 50 day simple moving average of $24.11 and a 200 day simple moving average of $22.73.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.